Showing 1961-1970 of 2494 results for "".
- Orasis Pharmaceuticals Appoints Industry Veteran Paul Smith as President and Chief Operating Officerhttps://modernod.com/news/orasis-pharmaceuticals-appoints-industry-veteran-paul-smith-as-president-and-chief-operating-officer/2479112/Orasis Pharmaceuticals announced the appointment of Paul Smith as president and chief operating officer (COO). Mr. Smith brings over two decades of leadership in eye care. “I am excited to join Orasis Pharmaceuticals at such a pivotal time in the company’s h
- EyeCare Partners Promotes David Clark to Chief Executive Officerhttps://modernod.com/news/eyecare-partners-promotes-david-clark-to-chief-executive-officer/2479099/EyeCare Partners LLC announced the promotion of David A. Clark to chief executive officer, effective immediately. Mr. Clark joined EyeCare Partners as president in July 2020 after 20 years with MEDNAX Inc., where he was most recently ch
- Ora Appoints David P. Bingaman, DVM, PhD, in Newly Created Chief Development Officer Positionhttps://modernod.com/news/ora-appoints-david-p-bingaman-dvm-phd-in-newly-created-chief-development-officer-position/2479097/Ora announced that David P. Bingaman, DVM, PhD, D. ACVO has joined the company in a newly created role of Chief Development Officer (CDO). Dr. Bingaman will oversee clinical and nonclinical activities that directly impact Ora’s customers around the world. Ora’s clinical research spans all
- Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United Stateshttps://modernod.com/news/gyroscope-therapeutics-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states/2479087/Gyroscope Therapeutics announced it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO) in the United States. All American Depositary Shares (ADSS) to be sold in the proposed IPO will be
- Infectious Disease Researcher Appointed Inaugural Chief Scientific Officer at Mass Eye and Earhttps://modernod.com/news/infectious-disease-researcher-appointed-inaugural-chief-scientific-officer-at-mass-eye-and-ear/2479047/Michael S. Gilmore, PhD, a microbiologist who has led infectious disease efforts at leading research institutions, has been appointed the first Chief Scientific Officer at Mass Eye and Ear. Dr. Gilmore will assume the role on May 1, 2021. He has served as Director of the Infectious Disease
- AAO: Looks Like the Home Office is Here to Stay. Here’s How to Protect Your Eyeshttps://modernod.com/news/aao-looks-like-the-home-office-is-here-to-stay-heres-how-to-protect-your-eyes/2478962/As home and office space merged during the pandemic, many people said they spent more time in front of screens and suffered because of it. They complained of eye strain, headaches, and dry eye, and worried that they might be doing permanent damage to their vision. Now comes a
- jCyte Promotes Dr. Shannon Blalock to Chief Executive Officerhttps://modernod.com/news/jcyte-promotes-dr-shannon-blalock-to-chief-executive-officer/2478840/jCyte announced the Board of Directors has promoted Shannon Blalock, PharmD, to Chief Executive Officer, and an elected member of the Board. Dr. Blalock joined jCyte last year as its Chief Operating Officer. “I am thrilled to announce the appointment of Shannon as jCyte’s new CEO at this i
- Neurophth Therapeutics Appoints Qiutang Li, PhD, as Chief Scientific Officerhttps://modernod.com/news/neurophth-therapeutics-appoints-qiutang-li-phd-as-chief-scientific-officer/2478800/Wuhan Neurophth Biotechnology, a developer of AAV-delivered gene therapies for the treatment of ocular diseases, announced the appointment of Qiutang Li, PhD, as Chief Scientific Officer. She will be mainly responsible for the company’s global R&D, IND portfolio strategy, and the establ
- Center For Sight is the First Practice Worldwide to Offer the OptiBlue IOLhttps://modernod.com/news/center-for-sight-is-the-first-practice-worldwide-to-offer-the-optiblue-iol/2478793/Center For Sight, which operates 14 eye clinics and surgery centers in Southwest Florida, is the first eye care practice to offer the new OptiBlue IOLs (Johnson & Johnson Vision), an advanced intraocular lens technology that filters violet light to improve contrast and clarity for cataract pa
- Oxurion NV Appoints Prof Alan Stitt as Chief Scientific Officerhttps://modernod.com/news/oxurion-nv-appoints-prof-alan-stitt-as-chief-scientific-officer/2478775/Oxurion has announced the appointment of Professor Alan Stitt, PhD, as the company’s Chief Scientific Officer (CSO), effective January 19, 2021. This appointment follows the retirement of current CSO Jean Feyen, PhD, who has served in this position since joining the company in 2013. Dr. Feyen wil